Whole-genome sequencing reveals host factors underlying critical COVID-19.
Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, Russell CD, Malinauskas T, Wu Y, Millar J, Shen X, Elliott KS, Griffiths F, Oosthuyzen W, Morrice K, Keating S, Wang B, Rhodes D, Klaric L, Zechner M, Parkinson N, Siddiq A, Goddard P, Donovan S, Maslove D, Nichol A, Semple MG, Zainy T, Maleady-Crowe F, Todd L, Salehi S, Knight J, Elgar G, Chan G, Arumugam P, Patch C, Rendon A, Bentley D, Kingsley C, Kosmicki JA, Horowitz JE, Baras A, Abecasis GR, Ferreira MAR, Justice A, Mirshahi T, Oetjens M, Rader DJ, Ritchie MD, Verma A, Fowler TA, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Elliott P, Walsh T, Tenesa A, GenOMICC investigators, 23andMe investigators, COVID-19 Human Genetics Initiative, Fawkes A, Murphy L, Rowan K, Ponting CP, Vitart V, Wilson JF, Yang J, Bretherick AD, Scott RH, Hendry SC, Moutsianas L, Law A, Caulfield MJ, Baillie JK. · 2022
Read Whole-genome sequencing reveals host factors underlying critical COVID-19. by Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, Russell CD, Malinauskas T, Wu Y, Millar J, Shen X, Elliott KS, Griffiths F, Oosthuyzen W, Morrice K, Keating S, Wang B, Rhodes D, Klaric L, Zechner M, Parkinson N, Siddiq A, Goddard P, Donovan S, Maslove D, Nichol A, Semple MG, Zainy T, Maleady-Crowe F, Todd L, Salehi S, Knight J, Elgar G, Chan G, Arumugam P, Patch C, Rendon A, Bentley D, Kingsley C, Kosmicki JA, Horowitz JE, Baras A, Abecasis GR, Ferreira MAR, Justice A, Mirshahi T, Oetjens M, Rader DJ, Ritchie MD, Verma A, Fowler TA, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Elliott P, Walsh T, Tenesa A, GenOMICC investigators, 23andMe investigators, COVID-19 Human Genetics Initiative, Fawkes A, Murphy L, Rowan K, Ponting CP, Vitart V, Wilson JF, Yang J, Bretherick AD, Scott RH, Hendry SC, Moutsianas L, Law A, Caulfield MJ, Baillie JK. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9259496.txt.
Introduction
Kousathanas and co-authors use whole-genome sequencing to find host factors behind critical COVID-19. Critical illness from this infection stems from immune-driven lung injury. The GenOMICC study compares the genomes of the critically ill with population controls. That contrast can expose disease pathways fit for drug targeting.
The team sequenced 7,491 critically ill people and compared them with 48,400 controls. They found and replicated 23 separate variants tied to critical disease. Sixteen of those links were new. The genes involved touch interferon signaling, white cell growth, and blood-type secretion. Further work points to several druggable targets, among them cell adhesion molecules. The picture that emerges has at least two paths to life-threatening illness.
Catalog record
| CREATOR | Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, Russell CD, Malinauskas T, Wu Y, Millar J, Shen X, Elliott KS, Griffiths F, Oosthuyzen W, Morrice K, Keating S, Wang B, Rhodes D, Klaric L, Zechner M, Parkinson N, Siddiq A, Goddard P, Donovan S, Maslove D, Nichol A, Semple MG, Zainy T, Maleady-Crowe F, Todd L, Salehi S, Knight J, Elgar G, Chan G, Arumugam P, Patch C, Rendon A, Bentley D, Kingsley C, Kosmicki JA, Horowitz JE, Baras A, Abecasis GR, Ferreira MAR, Justice A, Mirshahi T, Oetjens M, Rader DJ, Ritchie MD, Verma A, Fowler TA, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Elliott P, Walsh T, Tenesa A, GenOMICC investigators, 23andMe investigators, COVID-19 Human Genetics Initiative, Fawkes A, Murphy L, Rowan K, Ponting CP, Vitart V, Wilson JF, Yang J, Bretherick AD, Scott RH, Hendry SC, Moutsianas L, Law A, Caulfield MJ, Baillie JK. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 122 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Whole-genome sequencing reveals host factors underlying critical COVID-19 By Athanasios Kousathanas, Erola Pairo-Castineira, Konrad Rawlik, Alex Stuckey, Christopher A Odhams, Susan Walker, Clark D Russell, Tomas Malinauskas, Yang Wu, Jonathan Millar, Xia Shen, Katherine S Elliott Published in: Nature DOI: 10.1038/s41586-022-04576-6 ABSTRACT Abstract Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2–4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease. Subject terms: Respiratory distress syndrome, Genetics research, Genome-wide association studies, Infectious diseases, SARS-CoV-2 MAIN Critical illness in COVID-19 is both an extreme disease phenotype and a relatively homogeneous clinical definition; it includes patients with hypoxaemic respiratory failure5 with acute lung injury6, and excludes many patients with non-pulmonary clinical presentations7, who are known to have divergent responses to therapy8. In the UK, individuals in the critically ill group are younger, less likely to have significant comorbidity and more severely affected than a general hospitalized cohort5, characteristics which may amplify observed genetic effects. In addition, as development of critical illness is in itself a key clinical end-point for therapeutic trials8, using critical illness as a phenotype in genetic studies enables the detection of directly therapeutically relevant genetic effects1. Using microarray genotyping in 2,244 cases, we previously discovered that critical COVID-19 is associated with genetic variation in the host immune response to viral infection (OAS1, IFNAR2 and TYK2) and the inflammasome regulator DPP91. In collaboration with international groups, we extended these findings to include a variant near TAC4 (rs77534576)3. Several variants have been associated with milder phenotypes, including the ABO blood-type locus2, a pleiotropic inversion in chr17q21.319 and associations in five additional loci, including the T lymphocyte-associated transcription factor, FOXP43. An enrichment of rare loss-of-function variants in candidate interferon signalling genes has been reported4, but this has yet to be replicated at genome-wide significance thresholds10,11. In partnership with Genomics England, we performed whole-genome sequencing (WGS) to improve the resolution and deepen the fine-mapping of significant signals and thereby provide further biological insight into critical COVID-19. Here we present results from a cohort of 7,491 critically ill patients from 224 intensive care units, compared with 48,400 control individuals, describing the discovery and validation of 23 gene loci for susceptibility to critical COVID-19 (Extended Data Fig. 1). [Figure: Analysis workflow for GWAS and AVT analyses of this study.The cohorts displayed in yellow and green in the top box were processed with Genomics England Pipeline 2.0 and Illumina NSV4, respectively (see Methods on WGS Alignment and variant calling for details on differences between pipelines). We used individuals that were processed with either pipeline for the GWAS analyses and individuals processed only with Genomics England Pipeline 2.0 for the AVT analyses. The definition of the cases and controls was the same for GWAS and AVT, cases were the COVID-19 severe individuals for both, and controls included individuals from the 100,000 Genomes Project (100,000 Genomes Project) and also COVID-19 positive individuals that were recruited for this study and experienced only mild symptoms (COVID-mild).] GENOME-WIDE ASSOCIATION STUDY ANALYSIS After quality control procedures, we used a logistic mixed model regression, implemented in SAIGE12, to perform association analyses with unrelated individuals (critically ill cases, n = 7,491; controls, n = 48,400 (100,000 Genomes Project (100k) cohort, n = 46,770; mild COVID-19, n = 1,630) (Methods, Supplementary Table 2). A total of 1,339 of these cases were included in the primary analysis for our previous report1. Genome-wide association studies (GWASs) were performed separately for genetic ancestry groups (ncases/ncontrols: European (EUR) 5,989/42,891; South Asian (SAS) 788/3,793; African (AFR) 440/1,350; East Asian (EAS) 274/366), and combined by inverse-variance-weighted fixed effects meta-analysis using METAL (Methods). We established the independence of signals using GCTA-cojo, and we validated this with conditional analysis using individual-level data with SAIGE (Methods, Supplementary Table 6). To reduce the risk of spurious associations arising from genotyping or pipeline errors, we required supporting evidence from variants in linkage disequilibrium (LD) for all genome-wide-significant variants: observed z-scores for each variant were compared with imputed z-scores for the same variant, with discrepant values being excluded (see Methods, Supplementary Fig. 2). In population-specific analyses, we discovered 22 independent genome-wide-significant associations in the EUR ancestry group (Fig. 1, Supplementary Fig. 11, Table 1) at a P value threshold adjusted for multiple testing (2.2 × 10−08; Supplementary Table 5). In multi-ancestry meta-analysis, we identified an additional three independent genome-wide-significant association signals (Fig. 1, Table 1). [Figure: GWAS results for the EUR ancestry group, and multi-ancestry meta-analysis.Manhattan plots are shown on the left and quantile–quantile (QQ) plots of observed versus expected P values on the right, with genomic inflation (λ) displayed for each analysis. Highlighted results in blue in the Manhattan plots indicate variants that are LD-clumped (r2 = 0.1, P2 = 0.01, EUR LD) with the lead variants at each locus. Gene name annotation indicates genes that are affected by the predicted worst consequence type of each lead variant (annotation by Variant Effect Predictor (VEP)). For the HLA locus, the gene that was identified by HLA allele analysis is annotated. The GWAS was performed using logistic regression and meta-analysed by the inverse variant method. The red dashed line shows the Bonferroni-corrected P value: P = 2.2 × 10−8.] [Table: Lead variants from independent association signals in the per-population GWAS and multi-ancestry meta-analysis] To assess the sensitivity of our results to mismatches of demographic characteristics between cases and controls (Supplementary Figs. 9, 10), we performed an age-, sex- and body mass index (BMI)-matched case–control analysis (Supplementary Figs. 18–21). As there is a theoretical risk of mismatch between cases and 100,000 Genomes Project participants in risk factors for exposure (for example, shielding behaviour) or susceptibility to critical COVID-19 (for example, immunosuppression), we performed a sensitivity analysis using only the cohort with mild COVID-19 (see above; Supplementary Table 10). In both of these analyses, allele frequencies and directions of effect were concordant for all lead signals. We inferred credible sets of variants using Bayesian fine-mapping with